#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuropathy peripheral Exudative retinopathy Waldenstrom's macroglobulinaemia Antithrombin III deficiency Urea cycle disorder Factor IX deficiency Follicle centre lymphoma follicular grade I II – III refractory Chondrodystrophy Neurofibromatosis Myelodysplastic syndrome Myeloproliferative neoplasm Gaucher's disease type III Thermal burn Palmar-plantar erythrodysaesthesia syndrome Lymphangioma More trials…

    Learn about Rare Diseases

    Fragile X syndrome Fragile X syndrome – Diagnostics SAPHO syndrome – Diagnostics Sarcoidosis – Diagnostics Systemic sclerosis pulmonary – Diagnostics Chordoma – Treatment Ewing’s sarcoma recurrent – Life with Disease Primary mediastinal large B-cell lymphoma Rosai-Dorfman syndrome – Diagnostics Glomerulonephritis rapidly progressive – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lecanemab Apocynin BIIB115 Alemtuzumab Istaroxime Bdc-1001 Lucerastat Rbd5044 Sodium L-ALANINE Loperamide Hydrochloride Nilotinib Iron Sucrose IMA401 BUMETANIDE Somatropin Gad20-209-Fsp-A1 VTX-002 Alanine Olea Europaea Pollen Extract Lerodalcibep More therapies…

    Learn about Your Condition

    Juvenile idiopathic arthritis Gastrointestinal melanoma Alveolar bone defect Inner ear disorder Carotid arteriosclerosis Congenital pseudarthrosis Venous thrombosis Mantle cell lymphoma stage IV Vascular calcification Colorectal cancer Pruritus Metastases to biliary tract Pancreatitis acute Oesophageal adenocarcinoma Peritoneal sarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on Fludarabine, Melphalan, and Radiation for Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Preparing for Stem Cell Transplant.

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Melphalan
    • Fludarabine Phosphate
    • Tacrolimus
    Spain

  • Study on the Safety of NG004 for Patients with Acute Spinal Cord Injury

    Recruiting

    1 1 1
    Investigated Diseases:
    • Spinal cord injury cervical
    Investigated Drugs:
    • Ng004
    Germany

  • Study on Imaging Multiple Myeloma Patients Using Fluciclovine (18F) PET/CT

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Fluciclovine (18F)
    Norway

  • Study of Single Dose Psilocybin Treatment for Adults with Alcohol Use Disorder

    Recruiting

    1 1 1
    Investigated Diseases:
    • Alcohol use disorder
    Investigated Drugs:
    • Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
    Denmark

  • Study on the Effectiveness and Safety of DNL310 vs Idursulfase for Children and Young Adults with Mucopolysaccharidosis Type II

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor
    • Idursulfase
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Pembrolizumab
    France
Previous Page
1 … 418 419 420 421 422 … 1,651
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!